Safety of Direct Administration of AAV2 CU hCLN2, a Candidate Treatment for the Central Nervous System Manifestations of Late Infantile Neuronal Ceroid Lipofuscinosis, to the Brain of Rats and Nonhuman Primates

Hackett, Neil R.; Redmond, D. Eugene; Sondhi, Dolan; Giannaris, E. Lela; Vassallo, Elizabeth; Stratton, Jamie; Qiu, Jianping; Kaminsky, Stephen M.; Lesser, Martin L.; Fisch, Gene S.; Rouselle, Serge D.; Crystal, Ronald G.

doi:10.1089/hum.2005.16.1484

Cited by 57Lysosomal Storage Disorders ResearchVirus-based gene therapy researchRNA Interference and Gene Delivery

Safety of Direct Administration of AAV2 CU hCLN2, a Candidate Treatment for the Central Nervous System Manifestations of Late Infantile Neuronal Ceroid Lipofuscinosis, to the Brain of Rats and Nonhuman Primates

Hackett, Neil R., Redmond, D. Eugene, Sondhi, Dolan, Giannaris, E. Lela, Vassallo, Elizabeth, Stratton, Jamie, Qiu, Jianping, Kaminsky, Stephen M. +4 more·2005·Human Gene Therapy

DOI 10.1089/hum.2005.16.1484

Open this paper in CoChat — free account

Abstract

Late infantile neuronal ceroid lipofuscinosis (LINCL), a pediatric autosomal recessive neurodegenerative lysosomal storage disorder, results from mutations in the CLN2 gene and consequent deficiency in tripeptidyl-peptidase I (TPP-I) and progressive destruction of neurons. We have previously demonstrated that CNS gene transfer of AAV2(CU)hCLN2 (an AAV2-based vector expressing the human CLN2 cDNA) in rats and nonhuman primates mediates long-term TPP-I expression in the CNS neurons [Sondhi, D., Peterson, D.A., Giannaris, E.L., Sanders, C.T., Mendez, B.S., De, B., Rostkowski, A., Blancard, B., Bjugstad, K., Sladek, J.R., Redmond, D.E., Leopold, P.L., Kaminsky, S.M., Hackett, N.R., and Crystal, R.G. (2005). Gene Ther. 12, 1618-1632]. The present study tests the hypothesis that direct CNS administration of a clinical-grade AAV2(CU)hCLN2 vector to the CNS of rats and nonhuman primates at doses scalable to humans has a long-term safety profile acceptable for initiating clinical trials. Fischer 344 rats were injected bilaterally via the striatum with 2 x 10(10) particle units (PU) of AAV2(CU)hCLN2, using saline as a control. At 13, 26, and 52 weeks, vector and phosphate-buffered salineinjected rats were killed (n = 6 per time point), and blood, brain, and distant organs were assessed. There were no biologically significant differences between control and vector groups for complete blood count, serum chemistry, and neutralizing anti-AAV2 antibody levels. CNS administration of AAV2 CUhCLN2 did not result in any pathological changes in the brain that were attributable to the vector, although microscopic changes were observed along the track consistent with needle trauma. A total dose of 3.6 x 10(10) or 3.6 x 10(11) PU of AAV2(CU)hCLN2 was administered to the CNS of African Green monkeys at 12 locations, targeting the caudate nucleus, hippocampus, and overlying cortices. Monkeys (n = 3 at each dose) were killed 1, 13, 26, or 52 weeks after injection. Controls included sham-injected, saline-injected, and AAV2(CU)Null-injected (3.6 x 10(11) PU) monkeys. There were no biologically significant differences among vector-injected and control groups in any parameter of the general assessment, complete blood count, or serum chemistry assessed at multiple time points after vector administration. Importantly, no abnormal behavior was observed in any group in videotaped neurological assessment, where behaviors were quantified before administration and at multiple time points afterward. Histopathological examination of the CNS demonstrated that 1 week after administration, AAV2(CU)hCLN2 produced transient minor white matter edema with reactive glial cells in the corona radiata of the cerebrum along the injection track and in the surrounding white matter. This abnormality was not observed at 13, 26, or 52 weeks. Together with the long-term gene expression after gene transfer, these findings supported the initiation of clinical trials to assess the safety of AAV2(CU)hCLN2 administration to individuals with LINCL.

Integrity signals

Registry

Crossref · 10.1089/hum.2005.16.1484

Cites

74 of 74 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Statistical comparisons were considered significant if p < 0.01 because of the small sample size (n = 3/group) and daily variations in cell numbers and serum chemistries.
“Due to the small sample size (n = 3/group) and daily variations in cell numbers and serum chemistries, statistical comparisons were considered to be significant if p < 0.01.31,37,38”
From AAVrh.10-Mediated APOE2 Central Nervous System Gene Therapy for APOE4-Associated Alzheimer's Disease (2018) · cites this paper as [37]

Statistical principles in experimental design.
Winer, B. J. (1962) · McGraw-Hill Book Company · doi:10.1037/11774-000 · Cited by 27,137 · see citing works
Efficient selection for high-expression transfectants with a novel eukaryotic vector
Niwa, H., Yamamura, K., & Miyazaki, J. (1991) · Gene · doi:10.1016/0378-1119(91)90434-d · Cited by 5,135 · see citing works
Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy
Gao, G.-P., Alvira, M. R., Wang, L., Calcedo, R., Johnston, J., & Wilson, J. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182412299 · Cited by 1,520 · see citing works
Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield
Zolotukhin, S., Byrne, B. J., Mason, E. G., Zolotukhin, I., Potter, M., Chesnut, K. A., Summerford, C., Samulski, R. J., & Muzyczka, N. (1999) · Gene Therapy · doi:10.1038/sj.gt.3300938 · Cited by 1,317 · see citing works
Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector
Kay, M. A., Manno, C. S., Ragni, M. V., Larson, P. J., Couto, L. B., McClelland, A., Glader, B. E., Chew, A. K., Tai, S. J., Herzog, R. W., et al. (2000) · Nature Genetics · doi:10.1038/73464 · Cited by 1,019 · see citing works
Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector
Xiao, X., Li, J., & Samulski, R. J. (1996) · Journal of Virology · doi:10.1128/jvi.70.11.8098-8108.1996 · Cited by 913 · see citing works
AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B
Manno, C. S., Chew, A. J., Hutchison, S., Larson, P. J., Herzog, R. W., Arruda, V. R., Tai, S. J., Ragni, M. V., Thompson, A., Ozelo, M., et al. (2003) · Blood · doi:10.1182/blood-2002-10-3296 · Cited by 749 · see citing works
Novel Tools for Production and Purification of Recombinant Adenoassociated Virus Vectors
Grimm, D., Kern, A., Rittner, K., & Kleinschmidt, J. A. (1998) · Human Gene Therapy · doi:10.1089/hum.1998.9.18-2745 · Cited by 700 · see citing works
Association of Mutations in a Lysosomal Protein with Classical Late-Infantile Neuronal Ceroid Lipofuscinosis
Sleat, D. E., DONNELLY, R. J., Lackland, H., Liu, C., Sohár, I., Pullarkat, R. K., & Lobel, P. (1997) · Science · doi:10.1126/science.277.5333.1802 · Cited by 581 · see citing works
Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus
Herzog, R. W., Hagstrom, J. N., Kung, S.-H., Tai, S. J., Wilson, J. M., Fisher, K. J., & High, K. A. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.11.5804 · Cited by 474 · see citing works
Repeated Adeno-Associated Virus Serotype 2 Aerosol-Mediated Cystic Fibrosis Transmembrane Regulator Gene Transfer to the Lungs of Patients With Cystic Fibrosis
Moss, R. B., Rodman, D. M., Spencer, L. T., Aitken, M. L., Zeitlin, P. L., Waltz, D. A., Milla, C. E., Brody, A. S., Clancy, J. P., Ramsey, B. W., et al. (2004) · CHEST Journal · doi:10.1378/chest.125.2.509 · Cited by 389 · see citing works
Mitochondrial ATP synthase subunit c storage in the ceroid‐lipofuscinoses (Batten disease)
Palmer, D. N., Fearnley, I. M., Walker, J. E., Hall, N. A., Lake, B. D., Wolfe, L. S., Haltia, M., Martinus, R. D., & Jolly, R. D. (1992) · American Journal of Medical Genetics · doi:10.1002/ajmg.1320420428 · Cited by 360 · see citing works
The Neuronal Ceroid-Lipofuscinoses
Haltia, M. (2003) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/62.1.1 · Cited by 354 · see citing works
Efficient lentiviral transduction of liver requires cell cycling in vivo
Park, F., Ohashi, K., Chiu, W. S., Naldini, L., & Kay, M. A. (2000) · Nature Genetics · doi:10.1038/71673 · Cited by 323 · see citing works
Observed incidence of tumorigenesis in long-term rodent studies of rAAV vectors
Donsante, A., Vogler, C. A., Muzyczka, N., Crawford, J., Barker, J. E., Flotte, T. R., Campbell‐Thompson, M., Daly, T., & Sands, M. S. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301541 · Cited by 320 · see citing works
A Phase II, Double-Blind, Randomized, Placebo-Controlled Clinical Trial of tgAAVCF Using Maxillary Sinus Delivery in Patients with Cystic Fibrosis with Antrostomies
Wagner, J. A., Nepomuceno, I. B., Messner, A. H., Moran, M. L., Batson, E. P., Dimiceli, S., Brown, B. W., Desch, J. K., Norbash, A., Conrad, C., et al. (2002) · Human Gene Therapy · doi:10.1089/104303402760128577 · Cited by 265 · see citing works
Gene Therapy of Canavan Disease: AAV-2 Vector for Neurosurgical Delivery of Aspartoacylase Gene ( <i>ASPA</i> ) to the Human Brain
Janson, C., McPhee, S., Bilaniuk, L., Haselgrove, J., Testaiuti, M., Freese, A., Wang, D.-J., Shera, D., Hurh, P., Rupin, J., et al. (2002) · Human Gene Therapy · doi:10.1089/104303402760128612 · Cited by 255 · see citing works
Comprehensive assessment of hemorrhage risks and outcomes after stereotactic brain biopsy
Field, M., Witham, T. F., Flíckinger, J. C., et al. (2001) · Journal of neurosurgery · doi:10.3171/jns.2001.94.4.0545 · Cited by 254 · see citing works
Epitope Mapping of Human Anti-Adeno-Associated Virus Type 2 Neutralizing Antibodies: Implications for Gene Therapy and Virus Structure
Moskalenko, M., Chen, L., van Roey, M., Donahue, B. A., Snyder, R. O., McArthur, J. G., & Patel, S. D. (2000) · Journal of Virology · doi:10.1128/jvi.74.4.1761-1766.2000 · Cited by 253 · see citing works
Age-associated neuronal atrophy occurs in the primate brain and is reversible by growth factor gene therapy
Smith, D. E., Roberts, J. A., Gage, F. H., & Tuszynski, M. H. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.19.10893 · Cited by 244 · see citing works
Phase I Trial of Intranasal and Endobronchial Administration of a Recombinant Adeno-Associated Virus Serotype 2 (rAAV2)-CFTR Vector in Adult Cystic Fibrosis Patients: A Two-Part Clinical Study
Flotte, T. R., Zeitlin, P. L., Reynolds, T. C., Heald, A. E., Pedersen, P. S., Beck, S. E., Conrad, C., Brass‐Ernst, L., Humphries, M. R., Sullivan, K., et al. (2003) · Human Gene Therapy · doi:10.1089/104303403322124792 · Cited by 244 · see citing works
A Phase I Study of Aerosolized Administration of tgAAVCF to Cystic Fibrosis Subjects with Mild Lung Disease
Aitken, M. L., Moss, R. B., Waltz, D. A., Dovey, M. E., Tonelli, M. R., McNamara, S., Gibson, R. L., Ramsey, B. W., Carter, B. J., & Reynolds, T. C. (2001) · Human Gene Therapy · doi:10.1089/104303401753153956 · Cited by 238 · see citing works
Circulating anti-wild-type adeno-associated virus type 2 (AAV2) antibodies inhibit recombinant AAV2 (rAAV2)-mediated, but not rAAV5-mediated, gene transfer in the brain
Peden, C. S., Burger, C., Muzyczka, N., & Mandel, R. J. (2004) · Journal of Virology · doi:10.1128/jvi.78.12.6344-6359.2004 · Cited by 222 · see citing works
The Neuronal Ceroid-Lipofuscinoses (Batten Disease)
Mole, S., & Haltia, M. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-410529-4.00070-x · Cited by 220 · see citing works
Neonatal gene transfer leads to widespread correction of pathology in a murine model of lysosomal storage disease
Daly, T. M., Vogler, C. A., Levy, B. K., Haskins, M. E., & Sands, M. S. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.5.2296 · Cited by 204 · see citing works
Humoral Immunity to Adeno-Associated Virus Type 2 Vectors following Administration to Murine and Nonhuman Primate Muscle
Chirmule, N., Xiao, W., Truneh, A., Schnell, M. A., Hughes, J. V., Zoltick, P., & Wilson, J. M. (2000) · Journal of Virology · doi:10.1128/jvi.74.5.2420-2425.2000 · Cited by 198 · see citing works
Adeno-Associated Virus-Mediated Gene Transfer to the Brain: Duration and Modulation of Expression
Lo, W. D., Qu, G., Sferra, T. J., Clark, R., Chen, R., & Johnson, P. R. (1999) · Human Gene Therapy · doi:10.1089/10430349950018995 · Cited by 188 · see citing works
Behavioral Recovery in a Primate Model of Parkinson's Disease by Triple Transduction of Striatal Cells with Adeno-Associated Viral Vectors Expressing Dopamine-Synthesizing Enzymes
Muramatsu, S., Fujimoto, K.-I., Ikeguchi, K., Shizuma, N., Kawasaki, K., Ono, F., Shen, Y., Wang, L., Mizukami, H., Kume, A., et al. (2002) · Human Gene Therapy · doi:10.1089/10430340252792486 · Cited by 186 · see citing works
Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation.
During, M. J., Kaplitt, M. G., Stern, M. B., et al. (2001) · PubMed · Cited by 181 · see citing works
Pathology of the Fischer rat : reference and atlas
Boorman, G. A. (1990) · Academic Press eBooks · Cited by 178 · see citing works
Mutational Analysis of the Defective Protease in Classic Late-Infantile Neuronal Ceroid Lipofuscinosis, a Neurodegenerative Lysosomal Storage Disorder
Sleat, D. E., Gin, R. M., Sohár, I., Wisniewski, K. E., Sklower-Brooks, S., Pullarkat, R. K., Palmer, D. N., Lerner, T. J., Boustany, R.-M., Uldall, P. V., et al. (1999) · The American Journal of Human Genetics · doi:10.1086/302427 · Cited by 177 · see citing works
A gene transfer vector-cell line system for complete functional complementation of adenovirus early regions E1 and E4
Brough, D. E., Lizonová, A., Hsu, C., Kulesa, V., & Kovesdi, I. (1996) · Journal of Virology · doi:10.1128/jvi.70.9.6497-6501.1996 · Cited by 172 · see citing works
Latent Adeno-Associated Virus Infection Elicits Humoral but Not Cell-Mediated Immune Responses in a Nonhuman Primate Model
Hernandez, Y. J., Wang, J., Kearns, W. G., Loiler, S., Poirier, A. E., & Flotte, T. R. (1999) · Journal of Virology · doi:10.1128/jvi.73.10.8549-8558.1999 · Cited by 169 · see citing works
Erythropoietin gene therapy leads to autoimmune anemia in macaques
Gao, G., Lebherz, C., Weiner, D. J., Grant, R. L., Calcedo, R., McCullough, B. A., Bagg, A., Zhang, Y., & Wilson, J. M. (2003) · Blood · doi:10.1182/blood-2003-11-3852 · Cited by 156 · see citing works
Classical late infantile neuronal ceroid lipofuscinosis fibroblasts are deficient in lysosomal tripeptidyl peptidase I1
Vines, D. J., & Warburton, M. J. (1999) · FEBS Letters · doi:10.1016/s0014-5793(98)01683-4 · Cited by 155 · see citing works
Lack of Germline Transmission of Vector Sequences Following Systemic Administration of Recombinant AAV-2 Vector in Males
Arruda, V. R., Fields, P. A., Milner, R., Wainwright, L. M., Miguel, M. P. D., Donovan, P. J., Herzog, R. W., Nichols, T. C., Biegel, J. A., Razavi, M. K., et al. (2001) · Molecular Therapy · doi:10.1006/mthe.2001.0491 · Cited by 154 · see citing works
Safety and efficacy of factor IX gene transfer to skeletal muscle in murine and canine hemophilia B models by adeno-associated viral vector serotype 1
Arruda, V. R., Schüttrumpf, J., Herzog, R. W., Nichols, T. C., Robinson, N. A., Lotfi, Y., Mingozzi, F., Xiao, W., Couto, L. B., & High, K. A. (2003) · Blood · doi:10.1182/blood-2003-05-1446 · Cited by 149 · see citing works
Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy
Herzog, R. W., Fields, P. A., Arruda, V. R., Brubaker, J. O., Armstrong, E., McClintock, D., Bellinger, D. A., Couto, L. B., Nichols, T. C., & High, K. A. (2002) · Human Gene Therapy · doi:10.1089/104303402760128513 · Cited by 147 · see citing works
Convection-enhanced delivery of AAV-2 combined with heparin increases TK gene transfer in the rat brain
Nguyen, J. B., Sánchez‐Pernaute, R., Cunningham, J., & Bankiewicz, K. S. (2001) · Neuroreport · doi:10.1097/00001756-200107030-00037 · Cited by 135 · see citing works
The Human CLN2 Protein/Tripeptidyl-Peptidase I Is a Serine Protease That Autoactivates at Acidic pH
Lin, L., Sohár, I., Lackland, H., & Lobel, P. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008562200 · Cited by 135 · see citing works
Administration of a Replication-Deficient Adeno-Associated Virus Gene Transfer Vector Expressing the Human CLN2 cDNA to the Brain of Children with Late Infantile Neuronal Ceroid Lipofuscinosis
Crystal, R. G., Sondhi, D., Hackett, N. R., Kaminsky, S. M., Worgall, S., Stieg, P. E., Souweidane, M. M., Hosain, S. A., Heier, L., Ballon, D., et al. (2004) · Human Gene Therapy · doi:10.1089/hum.2004.15.1131 · Cited by 129 · see citing works
Self-citation
Neonatal Intramuscular Injection with Recombinant Adeno-Associated Virus Results in Prolonged beta-Glucuronidase Expression in Situ and Correction of Liver Pathology in Mucopolysaccharidosis Type VII Mice
Daly, T. M., Okuyama, T., Vogler, C. A., Haskins, M. E., Muzyczka, N., & Sands, M. S. (1999) · Human Gene Therapy · doi:10.1089/10430349950019219 · Cited by 127 · see citing works
Immediate and Long-Term Safety of Recombinant Adeno-associated Virus Injection into the Nonhuman Primate Muscle
Favre, D., Provost, N., Blouin, V., Blancho, G., Chérel, Y., Salvetti, A., & Moullier, P. (2001) · Molecular Therapy · doi:10.1006/mthe.2001.0494 · Cited by 122 · see citing works
Genetic immunization with adeno-associated virus vectors expressing herpes simplex virus type 2 glycoproteins B and D
Manning, W. C., Paliard, X., Zhou, S. Z., Bland, M., Lee, A. Y., Hong, K., Walker, C. M., Escobedo, J. A., & Dwarki, V. (1997) · Journal of Virology · doi:10.1128/jvi.71.10.7960-7962.1997 · Cited by 122 · see citing works
Acute Tissue Damage After Injections of Thrombin and Plasmin into Rat Striatum
Xue, M., & Bigio, M. R. D. (2001) · Stroke · doi:10.1161/hs0901.095408 · Cited by 118 · see citing works
Autoimmune anemia in macaques following erythropoietin gene therapy
Chenuaud, P., Larcher, T., Rabinowitz, J. E., Provost, N., Chérel, Y., Casadevall, N., Samulski, R. J., & Moullier, P. (2004) · Blood · doi:10.1182/blood-2003-11-3845 · Cited by 116 · see citing works
Immunological Aspects of Recombinant Adeno-Associated Virus Delivery to the Mammalian Brain
Mastakov, M. Y., Baer, K., Symes, C. W., Leichtlein, C. B., Kotin, R. M., & During, M. J. (2002) · Journal of Virology · doi:10.1128/jvi.76.16.8446-8454.2002 · Cited by 114 · see citing works
Route of Administration Determines Induction of T-Cell-Independent Humoral Responses to Adeno-Associated Virus Vectors
Xiao, W., Chirmule, N. B., Schnell, M. A., Tazelaar, J., Hughes, J. V., & Wilson, J. M. (2000) · Molecular Therapy · doi:10.1006/mthe.2000.0045 · Cited by 114 · see citing works
Immune Responses to Recombinant Adeno-Associated Virus Vectors: Putting Preclinical Findings into Perspective
Flotte, T. R. (2004) · Human Gene Therapy · doi:10.1089/1043034041361190 · Cited by 91 · see citing works
Intramuscular Administration of Recombinant Adeno-Associated Virus 2 α-1 Antitrypsin (rAAV-SERPINA1) Vectors in a Nonhuman Primate Model: Safety and Immunologic Aspects
Song, S., Scott-Jorgensen, M., Wang, J., Poirier, A. E., Crawford, J. M., Campbell‐Thompson, M., & Flotte, T. R. (2002) · Molecular Therapy · doi:10.1006/mthe.2002.0673 · Cited by 90 · see citing works
Striatal Delivery of rAAV-hAADC to Rats with Preexisting Immunity to AAV
Sanftner, L. M., Suzuki, B. M., Doroudchi, M. M., Feng, L., McClelland, A., Forsayeth, J. R., & Cunningham, J. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2003.12.005 · Cited by 89 · see citing works
AAV2-mediated CLN2 gene transfer to rodent and non-human primate brain results in long-term TPP-I expression compatible with therapy for LINCL
Sondhi, D., Peterson, D. A., Giannaris, E. L., Sanders, C. T., Mendez, B. S., De, B. P., Rostkowski, A. B., Blanchard, B. C., Bjugstad, K. B., Sladek, J. R., et al. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302549 · Cited by 86 · see citing works
Self-citation
Recombinant Adeno-associated Virus Serotypes 2– and 5–Mediated Gene Transfer in the Mammalian Brain: Quantitative Analysis of Heparin Co-infusion
Mastakov, M. Y., Baer, K., Kotin, R. M., & During, M. J. (2002) · Molecular Therapy · doi:10.1006/mthe.2002.0564 · Cited by 85 · see citing works
Safety of Adeno-Associated Virus as Cochlear Gene Transfer Vector: Analysis of Distant Spread Beyond Injected Cochleae
Kho, S. T., Pettis, R., Mhatre, A. N., et al. (2000) · Molecular Therapy · doi:10.1006/mthe.2000.0129 · Cited by 82 · see citing works
Severe long-term 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the vervet monkey (Cercopithecus aethiops sabaeus)
Taylor, J. R., Elsworth, J. D., Roth, R. H., Sladek, J. R., & Redmond, D. E. (1997) · Neuroscience · doi:10.1016/s0306-4522(97)00214-5 · Cited by 80 · see citing works
Self-citation
A Lysosomal Proteinase, the Late Infantile Neuronal Ceroid Lipofuscinosis Gene (CLN2) Product, Is Essential for Degradation of a Hydrophobic Protein, the Subunit c of ATP Synthase
Ezaki, J., Tanida, I., Kanehagi, N., et al. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0722573.x · Cited by 79 · see citing works
Production and characterization of recombinant human CLN2 protein for enzyme-replacement therapy in late infantile neuronal ceroid lipofuscinosis
Lin, L., & Lobel, P. (2001) · Biochemical Journal · doi:10.1042/0264-6021:3570049 · Cited by 77 · see citing works
Viral-mediated delivery of the late-infantile neuronal ceroid lipofuscinosis gene, TPP-I to the mouse central nervous system
Haskell, R. E., Hughes, S. M., Chiorini, J. A., Alisky, J. M., & Davidson, B. L. (2003) · Gene Therapy · doi:10.1038/sj.gt.3301843 · Cited by 69 · see citing works
Cellular Dynamics of Macrophages and Microglial Cells in Reaction to Stab Wounds in Rat Cerebral Cortex
Fujita, T., Yoshimine, T., Maruno, M., & Hayakawa, T. (1998) · Acta Neurochirurgica · doi:10.1007/s007010050095 · Cited by 66 · see citing works
Oral Administration of Recombinant Adeno-Associated Virus Elicits Human Immunodeficiency Virus-Specific Immune Responses
Xin, K.-Q., Ooki, T., Mizukami, H., Hamajima, K., Okudela, K., Hashimoto, K., Kojima, Y., Jounai, N., Kumamoto, Y., Sasaki, S., et al. (2002) · Human Gene Therapy · doi:10.1089/10430340260201662 · Cited by 62 · see citing works
Safety of adeno-associated virus gene therapy vectors: a current evaluation
Monahan, P. E., Jooss, K. U., & Sands, M. S. (2002) · Expert Opinion on Drug Safety · doi:10.1517/14740338.1.1.79 · Cited by 61 · see citing works
Intracranial Administration of Adenovirus Expressing HSV-TK in Combination with Ganciclovir Produces a Dose-Dependent, Self-Limiting Inflammatory Response
Smith, J. G., Raper, S. E., Wheeldon, E. B., Hackney, D. B., Judy, K. D., Wilson, J. M., & Eck, S. L. (1997) · Human Gene Therapy · doi:10.1089/hum.1997.8.8-943 · Cited by 59 · see citing works
Behavioral Effects of MPTP Administration in the Vervet Monkey
Taylor, J. R., Elsworth, J. D., Roth, R. H., Sladek, J. R., & Redmond, D. E. (1994) · Springer eBooks · doi:10.1007/978-1-4899-1447-7_6 · Cited by 55 · see citing works
Self-citation
Adenovirus-Mediated Transgene Expression in Nonhuman Primate Brain
Bohn, M. C., Choi-Lundberg, D. L., Davidson, B. L., Léránth, C., Kozlowski, D. A., Smith, J. C., O’Banion, M. K., & Redmond, D. E. (1999) · Human Gene Therapy · doi:10.1089/10430349950018166 · Cited by 54 · see citing works
Self-citation
Origin and fate of neural macrophages in a stab wound of the brain of the young rat.
Kaur, C., Ling, E., & Wong, W. C. (1987) · PubMed · Cited by 51 · see citing works
Erythropoetin accelerates hematocrit recovery in post-surgical anemia.
Atabek, U. M., Álvarez, R., Pello, M. J., et al. (1995) · PubMed · Cited by 48 · see citing works
Retinal Degeneration in Retinitis Pigmentosa and Neuronal Ceroid Lipofuscinosis: An Overview
Birch, D. G. (1999) · Molecular Genetics and Metabolism · doi:10.1006/mgme.1999.2829 · Cited by 44 · see citing works
Feasibility of Gene Therapy for Late Neuronal Ceroid Lipofuscinosis
Sondhi, D. (2001) · Archives of Neurology · doi:10.1001/archneur.58.11.1793 · Cited by 37 · see citing works
Self-citation
Direct Exposure of Mouse Spermatozoa to Very High Concentrations of a Serotype-2 Adeno-Associated Virus Gene Therapy Vector Fails to Lead to Germ Cell Transduction
Couto, L., Parker, A. E., & Gordon, J. W. (2004) · Human Gene Therapy · doi:10.1089/104303404322886138 · Cited by 37 · see citing works
Potential for germ line transmission after intramyocardial gene delivery by adeno-associated virus
Pachori, A. S., Melo, L. G., Zhang, L., Loda, M. F., Pratt, R. E., & Dzau, V. J. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2003.11.140 · Cited by 29 · see citing works
Quantitative Analysis of Transgene Protein, mRNA, and Vector DNA Following Injection of an Adenoviral Vector Harboring Glial Cell Line-Derived Neurotrophic Factor into the Primate Caudate Nucleus
Kozlowski, D. A., Bremer, E., Redmond, D. E., George, D., Larson, B., & Bohn, M. C. (2001) · Molecular Therapy · doi:10.1006/mthe.2000.0256 · Cited by 24 · see citing works
Self-citation
Preclinical Gene Therapy Studies for Hemophilia Using Adeno-Associated Virus (AAV) Vectors
Couto, L. (2004) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-2004-825630 · Cited by 21 · see citing works
Accumulation of mitochondrial ATP synthase subunit c in muscle in a patient with neuronal ceroid lipofuscinosis (late infantile form)
Umehara, F., Higuchi, I., Tanaka, K. A. K., et al. (1997) · Acta Neuropathologica · doi:10.1007/s004010050661 · Cited by 12 · see citing works
The compensatory ?rebound? of reactive astrogliosis: glial fibrillary acidic protein immunohistochemical analysis of reactive astrogliosis after a puncture wound to the brain of rats with portocaval anastomosis
Kaufmann Robert, C., Chang, Z., Shih, H., et al. (1991) · Acta Neuropathologica · doi:10.1007/bf00310926 · Cited by 10 · see citing works

Flagged first, then by citations

Sorted by citations

Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA
Worgall, S., Sondhi, D., Hackett, N. R., Kosofsky, B., Kekatpure, M. V., Neyzi, N., Dyke, J. P., Ballon, D., Heier, L., Greenwald, B. M., et al. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.022 · Cited by 402 · see citing works
Self-citation
Enhanced Survival of the LINCL Mouse Following CLN2 Gene Transfer Using the rh.10 Rhesus Macaque-derived Adeno-associated Virus Vector
Sondhi, D., Hackett, N. R., Peterson, D. A., Stratton, J., Baad, M., Travis, K. M., Wilson, J. M., & Crystal, R. G. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300049 · Cited by 170 · see citing works
Self-citation
AAVrh.10-Mediated APOE2 Central Nervous System Gene Therapy for APOE4-Associated Alzheimer's Disease
Rosenberg, J. B., Kaplitt, M. G., De, B. P., Chen, A., Flagiello, T., Salami, C., Pey, E., Zhao, L., Ricart Arbona, R. J., Monette, S., et al. (2018) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2017.231 · Cited by 169 · see citing works
Self-citation
Clinical Applications Involving CNS Gene Transfer
Kantor, B., McCown, T., Leone, P., & Gray, S. J. (2014) · Advances in Genetics · doi:10.1016/b978-0-12-800149-3.00002-0 · Cited by 74 · see citing works
Comparative Efficacy and Safety of Multiple Routes of Direct CNS Administration of Adeno-Associated Virus Gene Transfer Vector Serotype rh.10 Expressing the Human Arylsulfatase A cDNA to Nonhuman Primates
Rosenberg, J. B., Sondhi, D., Rubin, D. G., Monette, S., Chen, A., Cram, S., De, B. P., Kaminsky, S. M., Sevin, C., Aubourg, P., et al. (2014) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2013.239 · Cited by 58 · see citing works
Self-citation
Safety of Direct Intraparenchymal AAVrh.10-Mediated Central Nervous System Gene Therapy for Metachromatic Leukodystrophy
Rosenberg, J. B., Chen, A., De, B. P., Dyke, J. P., Ballon, D. J., Monette, S., Ricart Arbona, R. J., Kaminsky, S. M., Crystal, R. G., & Sondhi, D. (2021) · Human Gene Therapy · doi:10.1089/hum.2020.269 · Cited by 41 · see citing works
Self-citation
Controlled dissemination of AAV vectors in the primate brain
Varenika, V., Kells, A. P., Valles, F., Hadaczek, P., Forsayeth, J., & Bankiewicz, K. S. (2009) · Progress in Brain Research · doi:10.1016/s0079-6123(09)17511-8 · Cited by 33 · see citing works
Preclinical Toxicity Evaluation of AAV for Pain: Evidence from Human AAV Studies and from the Pharmacology of Analgesic Drugs
Pleticha, J., Heilmann, L. F., Evans, C. H., Asokan, A., Samulski, R. J., & Beutler, A. S. (2014) · Molecular Pain · doi:10.1186/1744-8069-10-54 · Cited by 21 · see citing works

Authors: Hackett, N. R., Redmond, D. E., Sondhi, D., Giannaris, E. L., Vassallo, E., Stratton, J., Qiu, J., Kaminsky, S. M., Lesser, M. L., Fisch, G. S., Rouselle, S. D., & Crystal, R. G.
Affiliations: Cornell University (US)
Yale University (US)
Northwell Health (US)
Charles River Laboratories (United States) (US)
ORCID: Hackett, Neil R.
Sondhi, Dolan
Giannaris, E. Lela
Stratton, Jamie
Qiu, Jianping
Kaminsky, Stephen M.
Lesser, Martin L.
Fisch, Gene S.
Crystal, Ronald G.
Venue: Human Gene Therapy
Publisher: SAGE Publications
Published: 2005-12
Volume: 16
Issue: 12
Pages: 1484-1503
ISSN: 1043-0342 (ISSN-L)
1557-7422
DOI: 10.1089/hum.2005.16.1484
OpenAlex: W2090920097
Cited by: 57
References: 74
Citations by year: 2026: 3 · 2025: 1 · 2024: 1 · 2023: 3 · 2021: 1 · 2020: 4 · 2019: 1 · 2018: 4 · 2016: 2 · 2015: 1 · 2014: 5 · 2013: 1 · 2012: 3
FWCI: 3.00
Type: journal article
Language: en
Open access: closed
Licence: www.liebertpub.com/nv/resources-tools/text-and-data-mining-policy/121/ (tdm)
Locations: Human Gene Therapy (publishedVersion)
PubMed (publishedVersion)
Funders: National Institute of Neurological Disorders and Stroke (U01NS047458)
Topics: Health Sciences › Medicine › Physiology › Lysosomal Storage Disorders Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Keywords: late infantile neuronal ceroid lipofuscinosis, tripeptidyl peptidase I, neurotoxicity, neuroinflammation, neurodegeneration, lysosomal storage disease, non-human primates, vervet monkey, rats
MeSH terms: Tripeptidyl-Peptidase 1, Dependovirus, Animals, Brain Edema, Central Nervous System, Chlorocebus aethiops, Genetic Vectors, Male, Neuronal Ceroid-Lipofuscinoses, Plasmids, Rats, Inbred F344, Genetic Therapy, Gene Expression, Gene Transfer Techniques, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Safety of Direct Administration of AAV2 CU hCLN2, a Candidate Treatment for the Central Nervous System Manifestations of Late Infantile Neuronal Ceroid Lipofuscinosis, to the Brain of Rats and Nonhuman Primates

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cites

Cited by

Related

Record

About these checks